Patents by Inventor Simeng Suy

Simeng Suy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8816095
    Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: August 26, 2014
    Assignee: Georgetown University
    Inventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige
  • Publication number: 20110230442
    Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Application
    Filed: August 17, 2009
    Publication date: September 22, 2011
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige
  • Patent number: 7074807
    Abstract: The present invention relates to methods for inducing cell death via activation of the caspase, SAPK, and apoptotic signaling cascades in a cell comprising administering to a cell a composition comprising tempo in a amount sufficient to induce death of said cell.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: July 11, 2006
    Assignee: Georgetown University
    Inventors: Usha Kasid, Simeng Suy
  • Publication number: 20040161775
    Abstract: The partial DNA sequence of new gene SHINC-1 is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SHINC-1 such as breast cancer, leukemia, lymphoma, melanoma, colorectal cancer, and lung cancer.
    Type: Application
    Filed: October 6, 2003
    Publication date: August 19, 2004
    Applicants: Georgetown University, NeoPharm, Inc.
    Inventors: Usha Kasid, Isamu Sakabe, Simeng Suy, Deepak Kumar, Imran Ahmad
  • Publication number: 20040024025
    Abstract: A method is provided for inducing cell death comprising administering to said cell a composition comprising tempo or a functional derivative of tempo.
    Type: Application
    Filed: March 13, 2003
    Publication date: February 5, 2004
    Applicant: Georgetown University
    Inventors: Usha Kasid, Simeng Suy